Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

Blujepa, the brand name for gepotidacin ... According to GSK, 16 million women in the U.S. struggle with UTIs each year, and ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

Blujepa is approved to treat females 12 and older with uncomplicated urinary tract infections, or UTIs. About half of all women will experience a UTI at some point in their lives, and about 30% ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

The FDA has approved the drug for use in women and girls over the age of 12 who suffer from uncomplicated urinary tract ...